| Literature DB >> 31109701 |
Xiaoyi Guo1, Tingdong Li1, Fugui Li2, Yarui Xu1, Han Wang1, Weimin Cheng2, Jiabao Tang1, Guoliang Zhou1, Honglin Chen3, Munhon Ng1, Mingfang Ji4, Shengxiang Ge5, Ningshao Xia1.
Abstract
The development of nasopharyngeal carcinoma (NPC), a common cancer in Southeastern Asia, is closely associated with Epstein-Barr virus (EBV) infection; however, the aetiological role of EBV in NPC pathogenesis remains enigmatic. The life cycle of EBV in NPC patients is defined as latency II, while the antibodies specific to lytic phase proteins, as well as lytic genes, were highly expressed in NPC patients. The correlation between antibody levels and the progression of NPC has been reported in some studies; however, most of these studies focused on IgA antibodies, and the results in different articles were not consistent. In this study, we concurrently determined the levels of IgA and IgG antibodies specific to six purified recombinant EBV antigens associated with different replication statuses of EBV: EBNA1 associated with latency II; the non-structural antigens Zta, TK, EA-D and EA-R associated with immediate-early and early lytic phases; and the EBV matrix protein VCA p18, which is involved in late lytic phase. Levels of antibodies specific to immediate-early and early antigens were correlated with the tumour progression, especially tumour size. The levels of antibodies specific to some lytic phase antigens were also correlated with lymph node inclusion and metastasis. However, the antibody specific to the latency II antigen EBNA1 was not correlated with either tumour size or metastasis. Consistent with previous transcriptome studies, the results suggested both the expression of lytic phase genes at the protein level and the intermittent reactivation of EBV in NPC patients.Entities:
Keywords: Antibody profile; Epstein-Barr virus; Nasopharyngeal carcinoma; Stage; Tumour progression
Mesh:
Substances:
Year: 2019 PMID: 31109701 DOI: 10.1016/j.oraloncology.2019.04.024
Source DB: PubMed Journal: Oral Oncol ISSN: 1368-8375 Impact factor: 5.337